Microglia: The "Brain's Cleanup Crew" Goes on Strike — and Gets Back to Work

MaisuZenwave

If you ask a family member what Alzheimer's disease actually is, most will tell you: plaques build up in the brain, and nerve cells die. That's not wrong, but it leaves out a key player — the brain has its own "cleanup crew" whose job is to clear out those plaques and other debris. The problem is that this crew walks off the job somewhere along the way.

 

This crew is called microglia. They are the brain's resident immune cells and make up the majority of the immune cells in the brain. In a healthy state, microglia constantly patrol the brain, swallowing dead cells, clearing protein fragments, and releasing growth factors that keep neurons healthy. Think of them as a combination of the janitor and the security guard in a residential complex: they sweep and take out the trash on a normal day, and they're the first on the scene when something goes wrong.

How the strike happens

In the early stages of Alzheimer's, microglia are actually doing their job. They move toward amyloid plaques and try to surround and digest them. A 2025 study in Nature Medicine even found that in the brains of patients receiving amyloid-targeting immunotherapy, microglia in a specific state directly participated in clearing plaques, with APOE and TREM2 as key regulators of the process[1].

 

The problem is the "long war." The plaques never get fully cleared, and microglia stay activated for so long that they slowly change. A 2026 review in Frontiers in Cell and Developmental Biology describes this clearly: microglial functional states are not simply "good" or "bad" but a dynamic continuum. Their behavior differs completely across disease stages and plaque loads. Early on, they can still help with phagocytosis and containment, but persistent inflammation and metabolic stress push some microglia into an "exhausted" state: phagocytic capacity drops, mitochondrial function goes awry, and they end up releasing more inflammatory signals instead[2].

 

In plain terms: the cleanup crew wasn't bad from the start. It worked too much overtime, burned out, and eventually started dumping trash on the floor itself.

Two "back-to-work plans" in 2026

If the problem is a strike, the approach is clear: find a way to get them working again. Two directions are worth watching in 2026.

 

The first is releasing the brake. A study published in Neuron in March 2026 focused on two genes: MS4A4A and MS4A6A. Large-scale genetic studies had already linked these genes to Alzheimer's risk, and they are expressed mainly in microglia. But what they actually do had remained unclear.

 

This study provided the answer: the proteins encoded by MS4A4A and MS4A6A form a complex that specifically suppresses another receptor called TREM2. What is TREM2? It's the "gas pedal" on the surface of microglia—activating TREM2 pushes microglia into a protective "disease-associated microglial" state, in which they more actively engulf plaques and protect neurons. MS4A4A/6A's job is to hold that gas pedal down so it can't be pressed.

 

The team validated this in vitro and in animal experiments: lowering MS4A4A or MS4A6A levels brought TREM2 up, and microglial phagocytosis and signaling recovered accordingly. In non-human primates, using an antibody to degrade MS4A4A likewise raised TREM2 levels. In other words, MS4A4A/6A are the brake pads — take the brake pads off, and the TREM2 gas pedal can finally be pressed[3].

 

The second direction is sending the cleanup crew a "call to action." A study published in Cell Death & Disease in April 2026 took a different route. A joint Spanish-Swiss team found that a small molecule called OLE can "rewire" microglia. In Alzheimer's model mice, OLE treatment prompted microglia to migrate actively toward amyloid plaques and surround them; plaque size and number both decreased, and neuronal damage was reduced along with them. The mice performed markedly better on cognitive tests.

 

More importantly, the study found corresponding evidence in brain tissue from human Alzheimer's patients: the PM20D1-OLE pathway is linked to microglial recruitment to plaques and to neuroprotection. The researchers framed it pragmatically: existing antibody therapies are "limited in effect, carry side effects, and are costly," whereas the OLE approach mobilizes the brain's own cleanup crew rather than injecting a pile of antibodies from the outside[4].

Why this matters for ordinary families

The amyloid antibody drugs approved over the past few years operate on the logic of "sending people in from outside to clear the plaques." That approach works, but only up to a point: clearance can't keep pace with deposition, side effects include brain swelling and microbleeds, and it requires regular intravenous infusions.

 

Microglia-based therapies work on a different logic: rather than doing the brain's work for it, they get the brain to do its own work again. If molecules like MS4A inhibitors or OLE are ultimately proven safe and effective, they may not require a trip to the hospital every two weeks for an infusion — they could be taken orally or dosed periodically, keeping the brain's own immune system in a state where it can do its job.

 

Of course, all of this is still at the research stage. The MS4A4A/6A finding was only published in March 2026, and the OLE animal data have only just come out. From "works in mice" to "usable in people" lies toxicology, dose-finding, and Phase 2 and Phase 3 trials — at least five to eight years. And microglia-based therapies carry a natural risk: an over-activated immune system can bring on inflammation in the brain. How to strike the balance between "getting the cleanup crew back to work" and "keeping the cleanup crew from running wild" is a question these drugs will have to answer.

 

But for families currently caring for a patient, this direction at least offers a new framework for understanding: Alzheimer's is not just nerve cells dying — it's the brain's self-maintenance system collapsing. And what has collapsed can, in principle, be repaired. The cleanup crew has gone on strike, and scientists are working out how to get it back on the job.

 

 

 

[1]van Olst, L., et al. (2025). Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer‘s disease. Nature Medicine, 31, 1418–1419.

https://www.nature.com/articles/s41591-025-03677-9

 

[2]Han, S., et al. (2026). Dynamic remodeling of microglial responses in Alzheimer’s disease: Heterogeneous states, spatiotemporal progression, and immunometabolic dysregulation. Frontiers in Cell and Developmental Biology, 14, 1929282.

https://pubmed.ncbi.nlm.nih.gov/42947965/

 

[3]Rosner, D., et al. (2026). MS4A4A and MS4A6A: New targets to enhance microglia protective function in Alzheimer’s disease. Neuron, 114(5), 791–794.

https://www.sciencedirect.com/science/article/abs/pii/S0896627326000887

 

[4]Sanchez-Mejias, E., et al. (2026). The PM20D1-OLE pathway induces microglia rewiring to ameliorate Alzheimer disease. Cell Death & Disease, 17, 561.

https://rd.springer.com/article/10.1038/s41419-026-08791-1

 

Back to blog

Leave a comment

微信图片_20241126172720.jpg__PID:4e768490-c967-4709-aaf3-eb1f14c41b23

zenwave

Precision 40Hz Gamma Wave Generator
Based on cutting-edge research
utilizing 40Hz Gamma Wave technology

BUY NOW